According to a recent LinkedIn post from Quell Therapeutics, the company is participating in the EULAR 2026 rheumatology congress in London, where it is presenting additional preclinical data on QEL-005, a targeted Treg cell therapy candidate. The post also notes an update on the CHILL clinical study in refractory rheumatoid arthritis and systemic sclerosis, including its multinational design across the U.K., Germany, and Spain.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that patient enrollment for CHILL is already under way at leading clinical centers in the U.K., with early clinical findings expected in Q1 2027. For investors, this timeline indicates that Quell remains in a capital- and data-intensive stage, but the advancing clinical program in serious autoimmune indications may enhance the company’s longer-term partnering potential and its positioning in the Treg cell therapy segment.
By highlighting QEL-005 and CHILL at a major European rheumatology meeting, the post points to ongoing efforts to build scientific and clinical visibility among key opinion leaders. This visibility could support future fundraising or strategic collaborations if forthcoming data are positive, while also underscoring development risk, given that meaningful value inflection is tied to clinical readouts that are still several years away.